Ann Hanham - Endocyte Independent Director
Director
Dr. Ann F. Hanham, Ph.D., is Independent Director of Endocyte, Inc., since November 2004. Dr. Hanham has served as a member of Board of Directors since November 2004. Dr. Hanham was the Managing Partner at BAR Capital Management, an investment adviser firm, since December 2013. Beginning in February 2000, Dr. Hanham was with Burrill Company, a VC and merchant banking firm, serving as a managing director from 2002 to November 2013. Dr. Hanham currently serves on the board of directors of SCYNEXIS, Inc., a pharmaceutical company. She previously served on the board of directors of BioMimetic Therapeutics, Inc., a biopharmaceutical company, from May 2001 to September 2006 Biotie Therapies, a drug discovery and development company, from March 2009 to April 2011 and Targacept, a biopharmaceutical company, from September 2005 to August 2006 since 2004.
| Age | 63 |
| Tenure | 20 years |
| Professional Marks | Ph.D |
| Phone | 765 463-7175 |
| Web | www.endocyte.com |
Endocyte Management Efficiency
The company has return on total asset (ROA) of (26.4801) % which means that it has lost $26.4801 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2763) %, meaning that it created substantial loss on money invested by shareholders. Endocyte's management efficiency ratios could be used to measure how well Endocyte manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 12.64 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Endocyte has a current ratio of 44.86, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Endocyte until it has trouble settling it off, either with new capital or with free cash flow. So, Endocyte's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Endocyte sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Endocyte to invest in growth at high rates of return. When we think about Endocyte's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ronald Ross | GMS Inc | 66 | |
| Larry Glasscock | Simon Property Group | 72 | |
| Yaron Dor | Shagrir Group Vehicle | 57 | |
| John Eyton | Magna International | 80 | |
| Stefan Selig | Simon Property Group | 58 | |
| Steven Gunby | Arrow Electronics | 63 | |
| Daniel Smith | Simon Property Group | 63 | |
| Richard Reilly | Aspen Aerogels | 71 | |
| Barbara Judge | Magna International | 70 | |
| Indira Samarasekera | Magna International | 68 | |
| Ramsay Battin | Aspen Aerogels | 43 | |
| Steven OBrien | Arrow Electronics | N/A | |
| Theron Gilliam | GMS Inc | 56 | |
| Fabian Garcia | Arrow Electronics | 61 | |
| Mitchell Lewis | GMS Inc | 58 | |
| Gail Hamilton | Arrow Electronics | 71 | |
| Robert Gervis | Aspen Aerogels | 58 | |
| Andrew Kerin | Arrow Electronics | 57 | |
| Peter Harder | Magna International | 62 | |
| Dana Yosef | Shagrir Group Vehicle | 39 | |
| Lawrence Worrall | Magna International | 73 | |
Management Performance
| Return On Equity | -0.28 | |||
| Return On Asset | -26.48 |
Endocyte Leadership Team
Elected by the shareholders, the Endocyte's board of directors comprises two types of representatives: Endocyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endocyte. The board's role is to monitor Endocyte's management team and ensure that shareholders' interests are well served. Endocyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endocyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ann Hanham, Independent Director | ||
| Christopher Leamon, VP of RandD | ||
| Marc Kozin, Director | ||
| Cooper Russell, Director | ||
| Patrick Machado, Director | ||
| Alison Armour, Chief Medical Officer | ||
| Michael Sherman, CFO and COO | ||
| David Mozley, Vice President - Imaging | ||
| Michael Brinkley, Vice President - Quality | ||
| Katherine Parker, Vice President of Human Resources | ||
| Lesley Russell, Independent Director | ||
| Keith Brauer, Independent Director | ||
| Ron Ellis, Co-Founder, CEO and President and Director | ||
| Philip Low, Co-Founder, Chief Scientific Officer and Director | ||
| Beth Taylor, Corporate Controller | ||
| Fred Middleton, Independent Director | ||
| Lesley Cooper, Director | ||
| Peter Meldrum, Director | ||
| Michael Andriole, CFO | ||
| Colin Goddard, Director | ||
| Scot Harper, VP of Clinical Operations | ||
| Erik Chelius, Vice President - CMC | ||
| John Aplin, Independent Chairman of the Board |
Endocyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endocyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | |||
| Return On Asset | -26.48 | |||
| Profit Margin | 0.0008 % | |||
| Operating Margin | (6.07) % | |||
| Current Valuation | 1.63 B | |||
| Shares Outstanding | 82.1 M | |||
| Shares Owned By Insiders | 4.85 % | |||
| Shares Owned By Institutions | 92.21 % | |||
| Number Of Shares Shorted | 8.34 M | |||
| Price To Earning | (4.45) X |
Pair Trading with Endocyte
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endocyte position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endocyte will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Endocyte Stock
If you are still planning to invest in Endocyte check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Endocyte's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |